McGregor Highlights Excitement and Future Directions Across GU Cancers

Bradley McGregor, MD, senior physician, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how ongoing trials hold the key for further breakthroughs in genitourinary (GU) cancer treatment.

McGregor explains that at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, there were not any major phase 3 trial breakthroughs in the space like we have been seeing in previous meetings. The focus, he explains, is now shifting towards refining existing data and exploring promising new avenues.

One intriguing area of exploration is the potential of kidney injury molecule-1 (KIM-1), a protein biomarker, in the adjuvant space for renal cell carcinoma. He highlights that at the ASCO meeting, we also saw presentations on patient-reported outcomes with the combination of enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda).

Overall, the focus at this meeting was on building upon existing knowledge and identifying promising directions for future research.

Transcription:

0:09 | I think overall, you know, we have been spoiled in GU here with these game changing phase 3 trials at each meeting, and [at] this meeting, we do not have those. And I think what we are seeing at this meeting is, we are seeing incremental steps, right? Sort of trying to take the data that we have and [see if we] can find signals there.

0:26 | I think the story with KIM-1 in the adjuvant space for renal cell carcinoma is intriguing. Might that be a biomarker that we can help identify which patients actually need to undergo the risks of adjuvant therapy for renal cell carcinoma, we saw data on patient reported outcomes with EV/pembrolizumab. So we are learning more about what we have. And I think we are slowly moving forward as we wait for ongoing trials.